JP2016503397A - 心不全関連リスクおよびそれらと関連する因子を減少させる方法 - Google Patents

心不全関連リスクおよびそれらと関連する因子を減少させる方法 Download PDF

Info

Publication number
JP2016503397A
JP2016503397A JP2015539720A JP2015539720A JP2016503397A JP 2016503397 A JP2016503397 A JP 2016503397A JP 2015539720 A JP2015539720 A JP 2015539720A JP 2015539720 A JP2015539720 A JP 2015539720A JP 2016503397 A JP2016503397 A JP 2016503397A
Authority
JP
Japan
Prior art keywords
subject
heart failure
peptide
inhibitors
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503397A5 (https=
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
ハニ エヌ サバー
ハニ エヌ サバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of JP2016503397A publication Critical patent/JP2016503397A/ja
Publication of JP2016503397A5 publication Critical patent/JP2016503397A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
JP2015539720A 2012-10-22 2013-10-22 心不全関連リスクおよびそれらと関連する因子を減少させる方法 Pending JP2016503397A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US61/716,867 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US61/822,752 2013-05-13
US201361839750P 2013-06-26 2013-06-26
US201361839743P 2013-06-26 2013-06-26
US61/839,743 2013-06-26
US61/839,750 2013-06-26
PCT/US2013/066228 WO2014066419A2 (en) 2012-10-22 2013-10-22 Methods for reducing risks associated with heart failure and factors associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018942A Division JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Publications (2)

Publication Number Publication Date
JP2016503397A true JP2016503397A (ja) 2016-02-04
JP2016503397A5 JP2016503397A5 (https=) 2016-12-08

Family

ID=50545459

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539720A Pending JP2016503397A (ja) 2012-10-22 2013-10-22 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2018018942A Pending JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2019104270A Pending JP2019194193A (ja) 2012-10-22 2019-06-04 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018018942A Pending JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2019104270A Pending JP2019194193A (ja) 2012-10-22 2019-06-04 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Country Status (13)

Country Link
US (4) US20150246092A1 (https=)
EP (5) EP2908839B1 (https=)
JP (3) JP2016503397A (https=)
KR (1) KR20160009008A (https=)
CN (2) CN105050613A (https=)
AU (2) AU2013334788A1 (https=)
BR (1) BR112015009072A2 (https=)
CA (1) CA2889155A1 (https=)
ES (1) ES3058737T3 (https=)
MX (1) MX2015005102A (https=)
NI (1) NI201500057A (https=)
PE (1) PE20151434A1 (https=)
WO (1) WO2014066419A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506190A (ja) * 2017-02-01 2020-02-27 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 利尿薬耐性の治療

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2017223533A1 (en) * 2016-06-24 2017-12-28 University Of Southern California Mentsh analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008046129A (ja) * 2006-08-16 2008-02-28 F Hoffmann La Roche Ag 進行型冠動脈疾患およびその合併症のインジケーターとしての心筋トロポニン
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
WO2011066374A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
WO2014210062A1 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008046129A (ja) * 2006-08-16 2008-02-28 F Hoffmann La Roche Ag 進行型冠動脈疾患およびその合併症のインジケーターとしての心筋トロポニン
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＴＨＥ ＡＭＥＲＩＣＡＮ ＣＯＬＬＥＧＥ ＯＦ ＣＡＲＤＩＯＬＯＧＹ, vol. 58, no. 1, JPN6017029014, 2011, pages 73 - 82, ISSN: 0003778840 *
岡山医学会雑誌, vol. 124, no. 1, JPN6017029018, April 2012 (2012-04-01), pages 71 - 73, ISSN: 0003778842 *
心臓, vol. 41, no. 7, JPN6017029016, 2009, pages 766 - 771, ISSN: 0003778841 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506190A (ja) * 2017-02-01 2020-02-27 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 利尿薬耐性の治療
JP2024164113A (ja) * 2017-02-01 2024-11-26 イェール・ユニヴァーシティー 利尿薬耐性の治療
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
US12600773B2 (en) 2017-02-01 2026-04-14 Novo Nordisk A/S Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele

Also Published As

Publication number Publication date
EP4711005A3 (en) 2026-04-22
EP2908839A2 (en) 2015-08-26
JP2019194193A (ja) 2019-11-07
ES3058737T3 (en) 2026-03-12
EP3586862B1 (en) 2021-12-08
CN110193077A (zh) 2019-09-03
CN105050613A (zh) 2015-11-11
JP2018109012A (ja) 2018-07-12
KR20160009008A (ko) 2016-01-25
US20230190859A1 (en) 2023-06-22
EP2908839B1 (en) 2019-08-21
PE20151434A1 (es) 2015-10-16
EP3586862A1 (en) 2020-01-01
AU2018206766A1 (en) 2018-08-09
HK1213799A1 (en) 2016-07-15
WO2014066419A2 (en) 2014-05-01
EP4397314A1 (en) 2024-07-10
EP2908839A4 (en) 2016-06-15
WO2014066419A3 (en) 2014-06-12
US20200360462A1 (en) 2020-11-19
US20150246092A1 (en) 2015-09-03
MX2015005102A (es) 2016-02-09
BR112015009072A2 (pt) 2017-07-04
EP4711005A2 (en) 2026-03-18
EP4005582A1 (en) 2022-06-01
AU2013334788A1 (en) 2015-06-04
EP4397314B1 (en) 2025-12-03
NI201500057A (es) 2015-07-16
US20250255929A1 (en) 2025-08-14
CA2889155A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
US20230190859A1 (en) Methods for reducing risks associated with heart failure and factors associated therewith
US12297502B2 (en) Methods and compositions for detecting and diagnosing diseases and conditions
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
HK40115529A (en) Treatment of left ventricular remodeling
HK40115529B (en) Treatment of left ventricular remodeling
HK1213799B (en) Methods for reducing risks associated with heart failure and factors associated therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180418